CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations

#CVRX CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting

www.stocktitan.net/news/CVRX/cv-rx-announce...

Pomerantz Law Firm Launches Investigation Into CVRx, Inc. for Potential Investor Misconduct Pomerantz Law Firm is probing claims concerning potential securities fraud at CVRx, Inc. that may affect investors significantly. Stay informed.

Pomerantz Law Firm Launches Investigation Into CVRx, Inc. for Potential Investor Misconduct #United_States #New_York #Securities_Fraud #Pomerantz #CVRx

Legal Investigation Underway for CVRx, Inc. Amidst Investor Claims of Possible Fraud Pomerantz Law Firm initiates an inquiry into CVRx, Inc. as investors respond to allegations of severe operational mismanagement. The situation raises concerns over compliance and governance.

Legal Investigation Underway for CVRx, Inc. Amidst Investor Claims of Possible Fraud #USA #New_York #Pomerantz_Law #Investor_Alert #CVRx

Pomerantz Law Firm Launches Investigation into CVRx, Inc. for Investor Claims The Pomerantz Law Firm is probing potential securities fraud involving CVRx, Inc., following disappointing financial announcements that impacted stock prices.

Pomerantz Law Firm Launches Investigation into CVRx, Inc. for Investor Claims #United_States #New_York #investigation #Pomerantz #CVRx

Pomerantz Law Firm Investigates Potential Securities Fraud In CVRx, Inc. Investors' Claims Pomerantz Law Firm is investigating securities fraud claims against CVRx, Inc. for its disappointing financial results that impacted investors significantly.

Pomerantz Law Firm Investigates Potential Securities Fraud In CVRx, Inc. Investors' Claims #USA #New_York #Securities_Fraud #Pomerantz #CVRx

CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population CVRx (NASDAQ: CVRX) announced initiation of BENEFIT-HF, a randomized trial planned to enroll 2,500 patients across ~150 U.S. and German centers to evaluate Barostim in a significantly expanded heart failure population. The primary endpoint is a composite of all-cause mortality and heart failure decompensation events. Enrollment is expected to begin in the first half of 2026. BENEFIT-HF will test Barostim in patients with LVEF 50% (vs current indication 35%) and NT-proBNP 5,000 pg/mL (vs current 1,600 pg/mL), potentially expanding the indicated population roughly threefold. The trial has CMS Category B IDE coverage to support patient access during the study period.

#CVRX CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

www.stocktitan.net/news/CVRX/cv-rx-announce...

CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy CVRx (NASDAQ: CVRX) confirmed that Category I CPT codes for baroreflex activation therapy using its Barostim device replaced Category III codes effective Jan 1, 2026. Category I CPT codes indicate an established procedure and can support broader adoption, coverage, and reimbursement across the U.S. healthcare system.CVRx said U.S. hospitals and physicians should update billing systems and begin using the new codes for procedures performed on or after Jan 1, 2026. The company stated it believes the change will enable more predictable and consistent reimbursement for Barostim patients and providers.

#CVRX CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy

www.stocktitan.net/news/CVRX/cv-rx-announce...

CVRx Reports Second Quarter 2025 Financial and Operating Results CVRx (NASDAQ: CVRX) reported its Q2 2025 financial results, achieving total revenue of $13.6 million, up 15% year-over-year. The company's U.S. Heart Failure revenue reached $12.1 million, also growing 15%. Active U.S. implanting centers increased 27% to 240 centers.Key developments include CMS's proposal to maintain Barostim in APC 1580 for 2026 with a $45,000 outpatient procedure payment, favorable physician fee proposals for Category I CPT codes, and the appointment of Brent Binkowski as COO. The company narrowed its FY2025 guidance to $55.0-$57.0 million in revenue with 83-84% gross margin.Despite revenue growth, CVRx reported a net loss of $14.7 million ($0.57 per share) and held $95.0 million in cash and equivalents as of June 30, 2025.

#CVRX CVRx Reports Second Quarter 2025 Financial and Operating Results

www.stocktitan.net/news/CVRX/cv-rx-reports-...

CVRx Secures Triple Medicare Payment Victory for Barostim: $45K Outpatient Coverage Confirmed Latest Medicare proposal maintains $45K payment while adding new coverage options for heart failure device. Multiple reimbursement wins boost adoption outlook. Get details.

#CVRX CVRx Announces Positive News on Outpatient Payment for Barostim

www.stocktitan.net/news/CVRX/cv-rx-announce...

CVRx Reports First Quarter 2025 Financial and Operating Results CVRx reported its Q1 2025 financial results with total revenue of $12.3 million, up 15% year-over-year. U.S. Heart Failure revenue reached $11.1 million, a 14% increase. The company expanded its U.S. presence to 227 active implanting centers, a 19% growth since March 31, 2024. Notable achievements include compelling real-world evidence showing Barostim's effectiveness, with an 85% reduction in heart failure hospital visits. However, financial challenges persist with a net loss of $13.8 million ($0.53 per share). The company updated its 2025 guidance, projecting total revenue between $55-58 million. CVRx maintains strong liquidity with $102.7 million in cash and cash equivalents, while continuing to invest in commercial expansion despite revenue growth not meeting expectations.

#CVRX CVRx Reports First Quarter 2025 Financial and Operating Results

www.stocktitan.net/news/CVRX/cv-rx-reports-...

Crude Oil Gains 1%; Walgreens Posts Upbeat Earnings - Bluejay Diagnostics (NASDAQ:BJDX), CVRx (NASDAQ:CVRX)

Crude Oil Gains 1%; Walgreens Posts Upbeat Earnings read more

www.benzinga.com/25/04/44696357/nasdaq-su...

#BJDX #CVRX #CYCU #Earnings #Equities #Mid #Day #Market #Update #News #NEXT

Event Attributes

CVRx Posts Mixed Q1 Earnings: 15% Growth Meets Headwinds as Expansion Continues CVRx achieves 15% revenue growth while expanding implanting centers to 227. Strong $102.7M cash position supports continued market expansion. Full analysis inside.

#CVRX CVRx Reports Preliminary First Quarter 2025 Financial Results

www.stocktitan.net/news/CVRX/cv-rx-reports-...

Groundbreaking Heart Failure Treatment Slashes Hospitalizations: New Clinical Data Stuns Medical Community New study of 306 patients shows CVRx's Barostim therapy dramatically reduces hospital visits and stay duration for heart failure patients, with 84-86% improvements.

#CVRX CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim

www.stocktitan.net/news/CVRX/cv-rx-announce...

CVRx Earnings Showcase: Heart Failure Treatment Propels 41% Revenue Explosion in Core Market CVRx reports 36% revenue growth to $15.3M in Q4, fueled by 41% surge in U.S. Heart Failure segment. Company expands footprint with 25% more implanting centers despite wider losses.

#CVRX CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

www.stocktitan.net/news/CVRX/cv-rx-reports-...

CVRx Reports Strong Q4 Growth: Revenue Surges 35% as Heart Failure Treatment Demand Accelerates CVRx delivers robust Q4 with revenue reaching $15.3M, driven by 41% growth in U.S. heart failure segment. Company projects continued momentum with 2025 revenue up to $65M.

#CVRX CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2024 Financial Results and Issues Fiscal 2025 Guidance

www.stocktitan.net/news/CVRX/cv-rx-reports-...

#CVRX CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference

www.stocktitan.net/news/CVRX/cv-rx-to-prese...

News; ( NASDAQ: #CVRX ) CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025

#StockMarket #News

BREAKING NEWS: ( NASDAQ: #CVRX ) CVRx announces new CPT Category I codes for Barostim

#StockMarket #News

Breaking News: ( NASDAQ: #CVRX ) (CVRX) Investment Analysis and Advice

#StockMarket #News